


Searching News Database: serotonin
HSMN NewsFeed - 4 Jan 2021
Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder
Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder
HSMN NewsFeed - 29 Jul 2019
Epygenix Therapeutics Receives IND Approval of EPX-100 for the Treatment of Dravet Syndrome
Epygenix Therapeutics Receives IND Approval of EPX-100 for the Treatment of Dravet Syndrome
HSMN NewsFeed - 11 Mar 2019
Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine
Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine
HSMN NewsFeed - 4 Feb 2019
Sojournix Appoints Ruth Thieroff-Ekerdt, M.D. As Senior Vice President And Chief Medical Officer
Sojournix Appoints Ruth Thieroff-Ekerdt, M.D. As Senior Vice President And Chief Medical Officer
HSMN NewsFeed - 5 Mar 2018
U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation
U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation
HSMN NewsFeed - 21 Jul 2017
Lexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo(R) (Telotristat Ethyl)
Lexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo(R) (Telotristat Ethyl)
HSMN NewsFeed - 23 Jun 2017
Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix(R) (vortioxetine) sNDA
Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix(R) (vortioxetine) sNDA
HSMN NewsFeed - 20 Aug 2015
S1 Biopharma Supports FDA Approval of First-Ever Treatment for Hypoactive Sexual Desire Disorder
S1 Biopharma Supports FDA Approval of First-Ever Treatment for Hypoactive Sexual Desire Disorder
HSMN NewsFeed - 9 Oct 2013
electroCore Signs $14 Million Deal with waveCore to Develop Wireless Vagus Nerve Stimulation Technology
electroCore Signs $14 Million Deal with waveCore to Develop Wireless Vagus Nerve Stimulation Technology
HSMN NewsFeed - 24 Jan 2011
Clinical Data, Inc. Announces FDA Approval of Viibryd(TM) (vilazodone HCl) for Major Depressive Disorder
Clinical Data, Inc. Announces FDA Approval of Viibryd(TM) (vilazodone HCl) for Major Depressive Disorder
HSMN NewsFeed - 4 Nov 2010
Euthymics Bioscience, Inc. Names Biotech Executive Timothy J. Barberich to Board of Directors
Euthymics Bioscience, Inc. Names Biotech Executive Timothy J. Barberich to Board of Directors
HSMN NewsFeed - 10 Aug 2010
Labopharm announces U.S. launch of OLEPTRO(TM) for treatment of major depressive disorder in adults
Labopharm announces U.S. launch of OLEPTRO(TM) for treatment of major depressive disorder in adults
HSMN NewsFeed - 1 Jul 2010
Eisai Inc. Enters Marketing and Supply Agreement with Arena Pharmaceuticals for Lorcaserin
Eisai Inc. Enters Marketing and Supply Agreement with Arena Pharmaceuticals for Lorcaserin
HSMN NewsFeed - 4 Dec 2009
US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
HSMN NewsFeed - 30 Nov 2009
FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder
FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder
HSMN NewsFeed - 11 Sep 2009
New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta(R)
New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta(R)
HSMN NewsFeed - 5 Jun 2009
Single Dose Palonosetron Prevents Emesis Induced by Chemotherapy in Non-Hodgkin's Lymphoma Patients
Single Dose Palonosetron Prevents Emesis Induced by Chemotherapy in Non-Hodgkin's Lymphoma Patients
HSMN NewsFeed - 2 Jun 2009
Clinical Data, Inc. Announces Positive Results from Second Phase III Trial of Vilazodone for Depression
Clinical Data, Inc. Announces Positive Results from Second Phase III Trial of Vilazodone for Depression
HSMN NewsFeed - 7 May 2009
New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
HSMN NewsFeed - 20 Apr 2009
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
HSMN NewsFeed - 23 Mar 2009
FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
HSMN NewsFeed - 28 Nov 2008
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
HSMN NewsFeed - 22 Sep 2008
Labopharm Submits New Drug Application to FDA for DDS-04A to Treat Major Depression
Labopharm Submits New Drug Application to FDA for DDS-04A to Treat Major Depression
HSMN NewsFeed - 25 Aug 2008
Patients Taking Cymbalta(R) Experienced Reduced Chronic Low Back Pain in New Study
Patients Taking Cymbalta(R) Experienced Reduced Chronic Low Back Pain in New Study
HSMN NewsFeed - 22 Aug 2008
Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder
Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder
HSMN NewsFeed - 27 Jun 2008
European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder
European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder
HSMN NewsFeed - 13 Jun 2008
Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
HSMN NewsFeed - 3 Jun 2008
Lexicon's Drug Candidate for Carcinoid Syndrome Receives Fast Track Status From the FDA
Lexicon's Drug Candidate for Carcinoid Syndrome Receives Fast Track Status From the FDA
HSMN NewsFeed - 28 May 2008
XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
HSMN NewsFeed - 15 May 2008
Wyeth's Pristiq, a New Treatment for Major Depressive Disorder in Adults, Now Available in U.S. Pharmacies
Wyeth's Pristiq, a New Treatment for Major Depressive Disorder in Adults, Now Available in U.S. Pharmacies
HSMN NewsFeed - 15 May 2008
Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension
Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension
HSMN NewsFeed - 15 Apr 2008
Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
HSMN NewsFeed - 7 Apr 2008
Endo Pharmaceuticals Provides Updates on FROVA(R) and CHRONOGESIC(R) Clinical Development Programs
Endo Pharmaceuticals Provides Updates on FROVA(R) and CHRONOGESIC(R) Clinical Development Programs
HSMN NewsFeed - 13 Mar 2008
Clinical Data, Inc. Initiates Second Pivotal Phase III Study of Vilazodone
Clinical Data, Inc. Initiates Second Pivotal Phase III Study of Vilazodone
HSMN NewsFeed - 6 Feb 2008
Apex Bioventures and Dynogen Pharmaceuticals Announce Definitive Merger Agreement
Apex Bioventures and Dynogen Pharmaceuticals Announce Definitive Merger Agreement
HSMN NewsFeed - 12 Dec 2007
New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
HSMN NewsFeed - 5 Dec 2007
New Data Reinforces the Superiority of Escitalopram Over Duloxetine for Acute Treatment of Depression
New Data Reinforces the Superiority of Escitalopram Over Duloxetine for Acute Treatment of Depression
HSMN NewsFeed - 30 Nov 2007
FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
HSMN NewsFeed - 18 Sep 2007
Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome
Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome
HSMN NewsFeed - 17 Sep 2007
Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
HSMN NewsFeed - 17 Sep 2007
Paladin and Labopharm Launch Tridural(TM) Once-Daily Tramadol Product in Canada
Paladin and Labopharm Launch Tridural(TM) Once-Daily Tramadol Product in Canada
HSMN NewsFeed - 21 Aug 2007
New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
HSMN NewsFeed - 10 Jul 2007
Noven to Acquire JDS Pharmaceuticals, Expanding Business Model & Broadening Product Pipeline
Noven to Acquire JDS Pharmaceuticals, Expanding Business Model & Broadening Product Pipeline
HSMN NewsFeed - 7 Jun 2007
Labopharm Initiates Phase III Clinical Study for Once-Daily Formulation of Trazodone
Labopharm Initiates Phase III Clinical Study for Once-Daily Formulation of Trazodone
HSMN NewsFeed - 21 May 2007
Data Suggest Cymbalta(R) Improved Functioning in Patients With Generalized Anxiety Disorder
Data Suggest Cymbalta(R) Improved Functioning in Patients With Generalized Anxiety Disorder
HSMN NewsFeed - 3 May 2007
Data Suggest Cymbalta(R) Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Data Suggest Cymbalta(R) Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
HSMN NewsFeed - 23 Mar 2007
NovaDel's European Formulation of Ondansetron Targeted for U.S. Zensana(TM)
NovaDel's European Formulation of Ondansetron Targeted for U.S. Zensana(TM)
HSMN NewsFeed - 20 Feb 2007
NovaDel Comments on Delay in Zensana(TM) Launch, as Announced by Hana BioSciences
NovaDel Comments on Delay in Zensana(TM) Launch, as Announced by Hana BioSciences
HSMN NewsFeed - 1 Feb 2007
Anavex Life Sciences Corp. Outlines Its Central Nervous System (CNS) Portfolio of Novel Therapeutics
Anavex Life Sciences Corp. Outlines Its Central Nervous System (CNS) Portfolio of Novel Therapeutics
HSMN NewsFeed - 5 Jan 2007
Hypnion Announces Positive and Robust Phase II Results for Novel Sleep Drug - HY10275
Hypnion Announces Positive and Robust Phase II Results for Novel Sleep Drug - HY10275
HSMN NewsFeed - 5 Dec 2006
Lexicon Genetics Files Investigational New Drug Application for LX1031 in Irritable Bowel Syndrome
Lexicon Genetics Files Investigational New Drug Application for LX1031 in Irritable Bowel Syndrome
HSMN NewsFeed - 23 Oct 2006
New Data for Zelnorm(R) Demonstrate Relief of Multiple Symptoms of Dysmotility-Type Dyspepsia
New Data for Zelnorm(R) Demonstrate Relief of Multiple Symptoms of Dysmotility-Type Dyspepsia
HSMN NewsFeed - 12 Sep 2006
Arena Pharmaceuticals Initiates Lorcaserin Phase 3 Obesity Clinical Trial
Arena Pharmaceuticals Initiates Lorcaserin Phase 3 Obesity Clinical Trial
HSMN NewsFeed - 18 Jul 2006
Valeant Pharmaceuticals Announces Availability of Zelapar(R) for Parkinson's Disease Patients
Valeant Pharmaceuticals Announces Availability of Zelapar(R) for Parkinson's Disease Patients
HSMN NewsFeed - 5 Jul 2006
NovaDel Announces Filing of NDA for the Zensana(TM) (Ondansetron HCl) Oral Spray
NovaDel Announces Filing of NDA for the Zensana(TM) (Ondansetron HCl) Oral Spray
HSMN NewsFeed - 22 May 2006
New Studies Examine SEROQUEL(R) in Combination With Antidepressant Therapy in Patients With Depression
New Studies Examine SEROQUEL(R) in Combination With Antidepressant Therapy in Patients With Depression
HSMN NewsFeed - 22 May 2006
New Data Presented on the Effect of Cymbalta(R) on Sexual Function in Depressed Patients
New Data Presented on the Effect of Cymbalta(R) on Sexual Function in Depressed Patients
HSMN NewsFeed - 15 May 2006
Clinical Data Announces Management Reorganization and Plan to Spin Off Vilazodone Business
Clinical Data Announces Management Reorganization and Plan to Spin Off Vilazodone Business
HSMN NewsFeed - 9 May 2006
Lilly Submits Cymbalta(R) Supplemental New Drug Application for Generalized Anxiety Disorder
Lilly Submits Cymbalta(R) Supplemental New Drug Application for Generalized Anxiety Disorder
Additional items found! 127
Members Archive contains
127 additional stories matching:
serotonin
(Password required)
serotonin
(Password required)
